Skip to main content
Premium Trial:

Request an Annual Quote

Consolidation History in the Bioinformatics Sector, as Tracked by BioInform, 2000-2003

Premium

2000
March: Paracel acquired by Celera Genomics (deal worth $283M)

August: Oxford Molecular acquired by Pharmacopeia (deal worth $27M)

September: Neomorphic acquired by Affymetrix (deal worth $70M)

October: Empaheon acquired by eBioinformatics (deal worth $11M)

December: Proteome acquired by Incyte (deal worth $77M)

 

2001
May:
Rosetta Inpharmatics acquired by Merck (deal worth $620M)

July: Synomics acquired by Accelrys (deal worth $4M)

July: Momentum acquired by Cellomics

November: Genomica acquired by Exelixis (deal worth $110M)

 

2002
January:
NetGenics acquired by Lion Bioscience (deal worth $17M)

February: ProteoMetrics closes, software acquired by Genomic Solutions (value not disclosed)

March: Entigen ceases operations

March: DoubleTwist closes

December: InforMax acquired by Invitrogen (deal worth $42M)

 

2003
January:
Structural Genomics, GeneFormatics plan merger

February: Viaken Systems closes

February: Phase-it acquired by Europroteome (value not disclosed)

March: Molecular Mining closes

April: Argentys (formerly Blackstone) acquired by TurboWorx (value not disclosed)

April: LabBook discontinues retail operations; Rescentris licenses technology

 

Filed under

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.